| Drug Name |
Troglitazone |
| Drug ID |
BADD_D02301 |
| Description |
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. |
| Indications and Usage |
For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
A10BG01 |
| DrugBank ID |
DB00197
|
| KEGG ID |
D00395
|
| MeSH ID |
D000077288
|
| PubChem ID |
5591
|
| TTD Drug ID |
D06XZW
|
| NDC Product Code |
Not Available |
| UNII |
I66ZZ0ZN0E
|
| Synonyms |
Troglitazone | 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T | CS 045 | CS-045 | CS045 | Rezulin | Prelay |
